These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25397574)

  • 1. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
    Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
    Castagna A; Galli L; Gianotti N; Torti C; Antinori A; Maserati R; d'Arminio Monforte A; Quiros-Roldan E; Salpietro S; Lazzarin A
    New Microbiol; 2013 Jul; 36(3):239-49. PubMed ID: 23912865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala.
    Laker E; Mambule I; Nalwanga D; Musaazi J; Kiragga A; Parkes-Ratanshi R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19792. PubMed ID: 25397536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
    Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
    J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability is more important than simplicity for treatment durability.
    Trottier B; Machouf N; Huchet E; Lavoie S; Vezina S; Boissonnault M; Charest L; Munoz M; Legault D; Longpré D; Thomas R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19765. PubMed ID: 25397509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.